Cytospire Therapeutics
Next-gen immune cell engagers for cancer
About
Cytospire Therapeutics develops next-generation gamma delta (γδ) T cell engagers as innovative cancer immunotherapies. Their proprietary multispecific antibodies are engineered to activate all γδ T cells, overcoming patient heterogeneity and targeting tumor antigens resistant to traditional CD3 engagers. The company aims to create potent, well-tolerated treatments for both solid and liquid tumors. Supported by experienced entrepreneurs and top biotech investors, Cytospire closed an oversubscribed £61M ($83M) Series A round to advance its pipeline into clinical trials.
Products
-
pan-gamma delta T cell engagers
— Multispecific antibodies that enhance and direct γδ T cells to develop safer, effective cancer therapies.
Customer sectors: oncology researchers, biopharma companies, clinical developers
Market research & competitive positioning
Source-backed TAM / SAM / SOM sizing, displacement analysis, and an interactive peer positioning map for Cytospire Therapeutics — available to members.
Related Companies
Other startups in Biotech & Therapeutics
